Corticosteroids for the Prevention of Atrial Fibrillation After Cardiac Surgery
This study has been terminated.
(Study has been completed as planned)
Sponsor:
Kuopio University Hospital
Collaborators:
Tampere University Hospital
Oulu University Hospital
Information provided by (Responsible Party):
Helena Pehkonen, Kuopio University Hospital
ClinicalTrials.gov Identifier:
NCT00442494
First received: March 1, 2007
Last updated: November 15, 2012
Last verified: October 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Atrial fibrillation is the most common arrhythmia to occur after cardiac surgery. Inflammatory response may be one etiological factor.
We hypothesized that intravenous corticosteroid administration after cardiac surgery prevents AF after cardiac surgery.
| Condition | Intervention |
|---|---|
|
Atrial Fibrillation |
Drug: intravenous hydrocortisone |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label |
| Official Title: | Feasibility of Corticosteroid in the Prevention of Atrial Fibrillation After Cardiac Surgery: A Prospective, Double-Blind Randomized Multicenter Trial |
Resource links provided by NLM:
Genetics Home Reference related topics:
familial atrial fibrillation
Drug Information available for:
Hydrocortisone acetate
Hydrocortisone
Hydrocortisone sodium succinate
Hydrocortisone cypionate
Hydrocortisone butyrate
Hydrocortisone valerate
Hydrocortisone probutate
U.S. FDA Resources
Further study details as provided by Kuopio University Hospital:
Primary Outcome Measures:
- Study couldn´t start due to investigator [ Time Frame: Study couldn´t start due to investigator ] [ Designated as safety issue: No ]Study couldn´t start due to investigator
Secondary Outcome Measures:
- Study couldn´t start due to investigator [ Time Frame: Study couldn´t start due to investigator ] [ Designated as safety issue: No ]Study couldn´t start due to investigator
Other Outcome Measures:
- Study couldn´t start due to investigator [ Time Frame: Study couldn´t start due to investigator ] [ Designated as safety issue: No ]Study couldn´t start due to investigator
| Enrollment: | 1 |
| Study Start Date: | October 2012 |
| Study Completion Date: | October 2012 |
| Primary Completion Date: | October 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Study couldn´t start due to investigator
Study couldn´t start due to investigator
|
Drug: intravenous hydrocortisone |
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Patients scheduled to undergo their first on-pump CABG, aortic valve replacement or combined aortic valve replacement and CABG were enrolled.
Exclusion Criteria:
- Previous episodes of AF or flutter
- Uncontrolled diabetes mellitus
- Systemic mycotic infection
- Active tuberculosis
- Cushing's syndrome
- Psychotic mental disorder
- Herpes Simplex keratitis
- Serum creatinine exceeding 200 µg/ml
- Patients were also excluded if they had a history of previous peptic ulcer or thrombophlebitis.
Contacts and Locations
More Information
No publications provided by Kuopio University Hospital
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Helena Pehkonen, assistant, Kuopio University Hospital |
| ClinicalTrials.gov Identifier: | NCT00442494 History of Changes |
| Other Study ID Numbers: | KUH5204515 |
| Study First Received: | March 1, 2007 |
| Last Updated: | November 15, 2012 |
| Health Authority: | Finland: Finnish Medicines Agency |
Keywords provided by Kuopio University Hospital:
|
Atrial fibrillation after cardiac surgery |
Additional relevant MeSH terms:
|
Atrial Fibrillation Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases Pathologic Processes Cortisol succinate Hydrocortisone acetate |
Hydrocortisone 17-butyrate 21-propionate Hydrocortisone Hydrocortisone-17-butyrate Anti-Inflammatory Agents Therapeutic Uses Pharmacologic Actions Dermatologic Agents |
ClinicalTrials.gov processed this record on May 21, 2013